Launchpad Therapeutics operates as an antibody-focused precision oncology company.
Launchpad Therapeutics has raised $10.0M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in December 2022.
Launchpad Therapeutics's investors include New Enterprise Associates, Versant Ventures, Black Diamond Therapeutics.
Launchpad Therapeutics is headquartered in San Francisco, United States.
Launchpad Therapeutics operates as an antibody-focused precision oncology company.
Launchpad Therapeutics is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Launchpad Therapeutics — Funding & Investors." VCBacked, December 29, 2022, https://www.vcbacked.co/company/launchpad-therapeutics. Accessed September 30, 2026.
VCBacked. (2022). Launchpad Therapeutics — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/launchpad-therapeutics
{{cite web |title=Launchpad Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/launchpad-therapeutics |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated